Travere Therapeutics Presents Data Reinforcing Clinical Benefit Of FILSPARI® (Sparsentan) In IgAN And Late-Breaking Presentation In FSGS At ASN Kidney Week 2024
Spartacus study, protect open. Presented new data further demonstrating the clinical benefit of filspari (sparsentan) in iga nephropathy (igan) and reinforcing its potential in. Tvtx), presented new data further demonstrating the clinical benefit of filspari. Travere therapeutics (tvtx) presented new data further demonstrating the clinical benefit of filspari in iga nephropathy and reinforcing its potential in focal segmental. Travere therapeutics presented new data further demonstrating the clinical benefit of filspari in iga nephropathy and reinforcing its potential in focal segmental.
Spartacus study, protect open.